AI assistant
Sending…
InMed Pharmaceuticals Inc. — Director's Dealing 2021
Oct 20, 2021
35386_dirs_2021-10-19_2a358897-1b8b-43e0-9477-02f824b79ff0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: InMed Pharmaceuticals Inc. (INM)
CIK: 0001728328
Period of Report: 2021-10-18
Reporting Person: HSU ERIC C (Sr. VP, Pre-Clinical Res/Dev)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-10-18 | Employee Stock Option (Right to Buy) | $1.40 | A | 35000 | Acquired | 2026-10-17 | Common shares (35000) | Direct |
Footnotes
F1: The options were granted on 10/18/2021 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.
More from InMed Pharmaceuticals Inc.
Regulatory Filings
2026
May 19
Regulatory Filings
2026
May 19
Interim / Quarterly Report
2026
May 6
Capital/Financing Update
2026
Apr 3
Capital/Financing Update
2026
Apr 3
Regulatory Filings
2026
Mar 23
Regulatory Filings
2026
Mar 20
Earnings Release
2026
Feb 12
Interim / Quarterly Report
2026
Feb 11
Major Shareholding Notification
2026
Jan 20